摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

isoquinolin-5-ylhydrazinium chloride | 102852-56-2

中文名称
——
中文别名
——
英文名称
isoquinolin-5-ylhydrazinium chloride
英文别名
5-Hydrazoisoquinoline hydrochloride;Isoquinolin-5-ylhydrazine;hydrochloride
isoquinolin-5-ylhydrazinium chloride化学式
CAS
102852-56-2
化学式
C9H9N3*ClH
mdl
——
分子量
195.651
InChiKey
GYMSPGJTYLYSEV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    252-253 °C

计算性质

  • 辛醇/水分配系数(LogP):
    1.94
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    50.9
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of New Heterocyclic Compounds Using 2-(3,3-dimethyl-1H-pyrroloisoquinolin-2(3H)-ylidene)malonaldehydes
    作者:Arash Afghan、Laia Roohi、Mehdi M. Baradarani、John A. Joule
    DOI:10.1002/jhet.1735
    日期:2014.5
    chloride 14 were converted via Fischer syntheses with 3‐methylbutan‐2‐one into indolenines, 2,3,3‐trimethyl‐3H‐pyrrolo[2,3‐f]isoquinoline 15 and 5‐bromo‐2,3,3‐trimethyl‐3H‐pyrrolo[3,2‐h]isoquinoline 16, respectively. Exposure of the indolenines to the Vilsmeier reagent produced diformyl compounds 17 and 18, which reacted with arylhydrazines to give the corresponding pyrazoles 19a, 19b, 19c, 19d, 19e,
    异喹啉-5- ylhydrazinium酰13和5-溴异喹啉-8- ylhydrazinium化物14转化经由费歇尔合成用3-甲基丁-2-酮为假吲哚,2,3,3-三甲基-3- ħ吡咯并[2,3- f ]异喹啉15和5--2,3,3-三甲基-3 H-吡咯并[3,2- h ]异喹啉16。将吲哚肾上腺素暴露于Vilsmeier试剂可制得二甲酰基化合物17和18,它们与芳基反应生成相应的吡唑19a,19b,19c,19d,19e,19f,19g,19h,19i和20a,20b,20c,20d,20e,20f,20g。17与硫脲的反应生成了嘧啶-2(1 H)-酮23或与盐酸羟胺异恶唑24的反应。
  • Structure−Activity Relationship Studies on <i>N</i>′-Aryl Carbohydrazide P2X<sub>7</sub> Antagonists
    作者:Derek W. Nelson、Kathy Sarris、Douglas M. Kalvin、Marian T. Namovic、George Grayson、Diana L. Donnelly-Roberts、Richard Harris、Prisca Honore、Michael F. Jarvis、Connie R. Faltynek、William A. Carroll
    DOI:10.1021/jm701516f
    日期:2008.5.1
    N'-Aryl acyl hydrazides were identified as P2X(7) receptor antagonists. Structure-activity relationship (SAR) studies evaluated functional activity by monitoring calcium flux inhibition in cell lines expressing recombinant human and rat P2X(7) receptors. Selected analogs were assayed in vitro for their capacity to inhibit release of cytokine IL-1 beta. Compounds with potent antagonist function were evaluated in vivo using the zymosan-induced peritonitis model. A representative compound effectively attenuated mechanical allodynia in a rat model of neuropathic pain.
  • Synthesis of 11H-pyridocarbazoles and derivatives. Comparison of their DNA binding and antitumor activity with those of 6H- and 7H-pyridocarbazoles
    作者:Elie Lescot、Gabriel Muzard、Judith Markovits、Joel Belleney、Bernard P. Roques、Jean Bernard Le Pecq
    DOI:10.1021/jm00159a028
    日期:1986.9
    The 8-methoxy- and 8-hydroxy-11H-pyrido[2,3-a]-, -[3,4-a]-, -[4,3-a]-, and [3,2-a]carbazoles were synthesized as potential DNA intercalating antitumor drugs. The structure of these compounds was confirmed by 1H NMR study including NOE experiments. The DNA binding properties of substituted and unsubstituted (8-H) heterocycles were determined by using their hydrochlorides or methiodides. These derivatives are able to bind to DNA with an affinity varying from 2.0 X 10(4) to 1.0 X 10(6) M-1, but most of them are unable to intercalate in contrast with the behavior of 6H- and 7H-pyridocarbazole analogues. The cytotoxicity of 11H-pyridocarbazoles, measured on L1210 cells in vitro, is much lower than those of 6H- and 7H-pyridocarbazole analogues.
  • Buu-Hoi,N.P.; Saint-Ruf,G., Israel Journal of Chemistry, 1963, vol. 1, p. 369 - 373
    作者:Buu-Hoi,N.P.、Saint-Ruf,G.
    DOI:——
    日期:——
  • PONASENKOVA, T. F.;AXVLEDIANI, R. N.;KURKOVSKAYA, L. N.;DIKOPOLOVA, V. V.+, XIMIYA GETEROTSIKL. SOEDIN., 1984, N 4, 490-494
    作者:PONASENKOVA, T. F.、AXVLEDIANI, R. N.、KURKOVSKAYA, L. N.、DIKOPOLOVA, V. V.+
    DOI:——
    日期:——
查看更多